These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 35427685)

  • 1. Vitiligo adverse events and associated medications as reported in the US Food and Drug Administration's Adverse Event Reporting System from 2016 to 2021.
    Learned C; Cohen SR; Alsukait S; Deverapalli S; Rosmarin D
    J Am Acad Dermatol; 2023 Jan; 88(1):197-199. PubMed ID: 35427685
    [No Abstract]   [Full Text] [Related]  

  • 2. The Weber effect and the United States Food and Drug Administration's Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010.
    Hoffman KB; Dimbil M; Erdman CB; Tatonetti NP; Overstreet BM
    Drug Saf; 2014 Apr; 37(4):283-94. PubMed ID: 24643967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
    Wysowski DK; Swartz L
    Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemical Leukoderma Associated with Methylphenidate Transdermal System: Data From the US Food and Drug Administration Adverse Event Reporting System.
    Cheng C; La Grenade L; Diak IL; Brinker A; Levin RL
    J Pediatr; 2017 Jan; 180():241-246. PubMed ID: 27745746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thromboembolic events in Janus kinase inhibitors: A pharmacovigilance study from 2012 to 2021 based on the Food and Drug Administration's Adverse Event Reporting System.
    Dong Z; Ye X; Chen C; Wang R; Liu D; Xu X; Zhou X; He J
    Br J Clin Pharmacol; 2022 Sep; 88(9):4180-4190. PubMed ID: 35466415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse drug and device reactions in the oral cavity: surveillance and reporting.
    Zavras AI; Rosenberg GE; Danielson JD; Cartsos VM
    J Am Dent Assoc; 2013 Sep; 144(9):1014-21. PubMed ID: 23989840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Lawyer-Submitted Reports on Signals of Disproportional Reporting in the Food and Drug Administration's Adverse Event Reporting System.
    Rogers JR; Sarpatwari A; Desai RJ; Bohn JM; Khan NF; Kesselheim AS; Fischer MA; Gagne JJ; Connolly JG
    Drug Saf; 2019 Jan; 42(1):85-93. PubMed ID: 30066315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detecting high-quality signals of adverse drug-drug interactions from spontaneous reporting data.
    Zhan C; Roughead E; Liu L; Pratt N; Li J
    J Biomed Inform; 2020 Dec; 112():103603. PubMed ID: 33153975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
    Welch HK; Kellum JA; Kane-Gill SL
    Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Food and Drug Administration's Drug Safety Oversight Board: an evolving paradigm for clinical input on drug safety topics.
    Grandinetti CA; Osborne SF
    Clin Pharmacol Ther; 2010 Aug; 88(2):269-74. PubMed ID: 20531466
    [No Abstract]   [Full Text] [Related]  

  • 11. Possible mechanisms in the induction of vitiligo-like hypopigmentation by topical imiquimod.
    Mashiah J; Brenner S
    Clin Exp Dermatol; 2008 Jan; 33(1):74-6. PubMed ID: 17979992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The US Food and Drug Administration's Sentinel Initiative: expanding the horizons of medical product safety.
    Robb MA; Racoosin JA; Sherman RE; Gross TP; Ball R; Reichman ME; Midthun K; Woodcock J
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():9-11. PubMed ID: 22262587
    [No Abstract]   [Full Text] [Related]  

  • 13. Immune checkpoint inhibitor-associated electrolyte disorders: query of the Food and Drug Administration Adverse Event Reporting System.
    Wanchoo R; Sakhiya V; Jhaveri KD
    Kidney Int; 2021 Oct; 100(4):945-947. PubMed ID: 34556301
    [No Abstract]   [Full Text] [Related]  

  • 14. Drug-induced vitiligo: a case/non-case study in Vigibase
    Anthony N; Bourneau-Martin D; Ghamrawi S; Lagarce L; Babin M; Briet M
    Fundam Clin Pharmacol; 2020 Dec; 34(6):736-742. PubMed ID: 32246859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physicians' liability for adverse drug reactions.
    Kaufman MB; Stoukides CA; Campbell NA
    South Med J; 1994 Aug; 87(8):780-4. PubMed ID: 8052883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns in spontaneous adverse event reporting among branded and generic antiepileptic drugs.
    Bohn J; Kortepeter C; Muñoz M; Simms K; Montenegro S; Dal Pan G
    Clin Pharmacol Ther; 2015 May; 97(5):508-17. PubMed ID: 25670505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pediatric drug surveillance and the Food and Drug Administration's adverse event reporting system: an overview of reports, 2003-2007.
    Johann-Liang R; Wyeth J; Chen M; Cope JU
    Pharmacoepidemiol Drug Saf; 2009 Jan; 18(1):24-7. PubMed ID: 19009550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How many deaths occur annually from adverse drug reactions in the United States?
    Chyka PA
    Am J Med; 2000 Aug; 109(2):122-30. PubMed ID: 10967153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteonecrosis of the Jaw in the United States Food and Drug Administration's Adverse Event Reporting System (FAERS).
    Zhang X; Hamadeh IS; Song S; Katz J; Moreb JS; Langaee TY; Lesko LJ; Gong Y
    J Bone Miner Res; 2016 Feb; 31(2):336-40. PubMed ID: 26288087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse drug events and near misses: who's counting?
    Wu AW
    Am J Med; 2000 Aug; 109(2):166-8. PubMed ID: 10967161
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.